Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease.

ABSTRACT:

Background

In Crohn's disease, higher adalimumab trough levels and negative anti-adalimumab-antibodies associate with better clinical and endoscopic outcomes. Intestinal ultrasound has become a relevant non-invasive method to monitor treatment. However, data on the association between adalimumab levels and bowel wall thickness measured with ultrasound is limited.

Objective

The purpose of this study was to examine the possible association between the sonographic transmural-thickness and adalimumab trough levels.

Methods

This prospective observational cohort study was conducted at Sheba Medical Center in 2014-2018. Crohn's disease patients on adalimumab maintenance therapy with intestinal ultrasound performed within <30 days of trough level measurement were included. As

SUBMITTER: Ungar B 

PROVIDER: S-EPMC7079273 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature